Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Neurocrine Biosciences, Inc., NBIX
Summary: Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.
- Last Price: $139.44
- Price Change: $0.34, 0.24%
- Yearly Gain: 43.44%
- Market Cap: $13.88B
- P/E Ratio: 56.68
Here are 3rd party ratings for NBIX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 36% (90 out of 252)
What is the sentiment on the street regarding Neurocrine Biosciences, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in NBIX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on NBIX before you decide to make any investment.
Click here for chart >>
Jazz Pharmaceuticals plc, JAZZ
Summary: Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.
- Last Price: $123.41
- Price Change: $2.51, 2.08%
- Yearly Gain: -10.56%
- Market Cap: $7.69B
- P/E Ratio: 20.2
Here are 3rd party ratings for JAZZ:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 36% (90 out of 252)
What is the sentiment on the street regarding Jazz Pharmaceuticals plc ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Balanced
- Investor Sentiment: Negative
- Hedge Fund signal: Medium Risk
If you are interested in JAZZ or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on JAZZ before you decide to make any investment.
Click here for chart >>
KalVista Pharmaceuticals, Inc., KALV
Summary: KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States.
- Last Price: $11.99
- Price Change: $0.06, 0.50%
- Yearly Gain: 70.80%
- Market Cap: $505.84M
- P/E Ratio: -3.84
Here are 3rd party ratings for KALV:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 36% (90 out of 252)
What is the sentiment on the street regarding KalVista Pharmaceuticals, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in KALV or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on KALV before you decide to make any investment.
Click here for chart >>
Inspire Medical Systems, Inc., INSP
Summary: Inspire Medical Systems Inc. is a medical technology company. It focused on the development and commercialization of solutions for obstructive sleep apnea. The company's proprietary Inspire therapy is a neurostimulation technology which provides treatment for moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc.is based in Minnesota, United States.
- Last Price: $199.23
- Price Change: $6.47, 3.36%
- Yearly Gain: -19.69%
- Market Cap: $5.89B
- P/E Ratio: -280.61
Here are 3rd party ratings for INSP:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 35% (88 out of 252)
What is the sentiment on the street regarding Inspire Medical Systems, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Buy
- Insider Signal: Buying
- Investor Sentiment: Negative
- Hedge Fund signal: Medium Risk
If you are interested in INSP or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on INSP before you decide to make any investment.
Click here for chart >>
Thanks for reading!